We’re excited to spotlight another valuable set of EBiSC iPSC tools for neurodegeneration research: SIGi001-A-15, SIGi001-A-17 and SIGi001-A-19.
These lines combine doxycycline-inducible Neurogenin 2 (NGN2) with different MAPT genotypes, enabling rapid generation of human neurons while modelling tau-driven disease biology in a controlled, isogenic system.
🔬 Key features:
- NGN2 cassette inserted at the AAVS1 locus for robust, inducible neuronal differentiation
- Rapid conversion to cortical-like neurons upon doxycycline treatment
- Isogenic background, differing only in MAPT genotype
🧠 Genotype breakdown:
- SIGi001-A-15: MAPT wild-type
- SIGi001-A-17: Homozygous exon10+16 variant
- SIGi001-A-19: Homozygous P301S + exon10+16 variant
This design enables clean, side-by-side investigation of how specific MAPT mutations influence tau pathology, neuronal phenotype, and function—without confounding background variation.
All three lines meet EBiSC quality control standards, ensuring reliability and reproducibility for downstream applications.
💡 By combining rapid NGN2-driven differentiation with precise genetic modelling, these lines provide a powerful platform to study tauopathies, including mechanisms relevant to frontotemporal dementia and Alzheimer’s disease.
A highly practical toolkit for accelerating translational neuroscience and therapeutic discovery.